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Introduction

• Myelodysplastic Syndrome (MDS) is a group of
disorders characterized by
abnormal myeloid maturation resulting in
peripheral cytopenia and bone marrow
dysplasia.
MDS with excess blasts (MDS-EB) is defined
as presence of 5-19% of blasts in the
peripheral blood or bone marrow and may
progress to AML with blast percentage >20%.
• Sweet Syndrome (SS) is a rare inflammatory
skin condition that can be secondary to
chemotherapy or the underlying malignancy
associated with AML and MDS in adults,
however, is particularly rare in children.
pathophysiology is thought to include
hypersensitivity reactions, cytokine
dysregulation especially G-CSF and genetic
susceptibility to the disease process.
• Major diagnostic criteria include
abrupt onset of painful erythematous
plaques/nodules
histopathologic evidence of sterile
neutrophilic panniculitis.
• Minor criteria include
excellent response to steroids,
underlying malignancy
three of the following: ESR >20 mm/hr,
CRP, >8,000 leukocytes and
>70 percent neutrophils.
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Case Report

• We present a case of a 4-year-old male with SS associated with MDS-EB
undergoing chemotherapy.
• Patient had previously failed therapy with Azacytidine now admitted for
bridge chemotherapy with cytarabine and Erwinia L-asparaginase as per
modified AAML1031.
• Despite morphine, pain associated with these lesions worsened, hindering
ambulation. He had similar nodules during previous induction cycles
starting around his ANC nadir.
• A biopsy showed patchy predominant lobular neutrophilic panniculitis and
focal neutrophilic folliculitis without malignant infiltration.

Discussion

• Laboratory results remarkable for ESR 67, CRP
302, ferritin 1,398.
• These above findings and the patient’s clinical
presentation course supported the clinical
diagnosis of SS.
• Given his immunosuppressive status, steroid
treatment was deferred.
• Patient was treated with ketorolac and
supportive care, and the lesions and pain
gradually improved as his ANC counts
recovered with a similar pattern to prior cycles.

Conclusion

• This atypical presentation of SS presents the
first case report of a pediatric patient with SS
secondary to MDS-EB.
• An abnormal response in this patient’s
endogenous G-CSF production for promoting
bone marrow recovery is proposed to be the
trigger that led to development of SS.
• This response observed with anti-inflammatory
treatment poses the possibility of considering
this treatment as an alternative for pain control
during the peak of immunosuppressive state
while undergoing chemotherapy.
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